Ingenu: Psycheceutical to Conduct the First Ever Phase I and II Clinical Trials of a Novel Ketamine Topical Cream to Treat PTSD

(marketscreener.com) Psycheceutical enters into agreement with iNGENū to conduct human clinical trials of NeuroDirect ketamine topical in AustraliaPhase I trial will study 20 people to test the safety, tolerability, and pharmacokinetics of a single dose of NeuroDirect ketaminePhase II trial will study 115...https://www.marketscreener.com/quote/stock/BLUE-WATER-VENTURES-INTER-120794578/news/Psycheceutical-to-Conduct-the-First-Ever-Phase-I-and-II-Clinical-Trials-of-a-Novel-Ketamine-Topical-42997296/?utm_medium=RSS&utm_content=20230215